Key Highlights
- Lumexa Imaging shares are trading down 3.63% at $15.37 versus a prior close of $15.95.
- The stock jumped 14.58% on Wednesday after third quarter results.
- Revenue rose 5% to $272 million, and adjusted EPS was $0.26.
- 2026 adjusted EPS guidance was raised to $0.86 to $0.90 from $0.71 to $0.77.
- Net Leverage fell to 3.5 times from 5.6 times a year ago.
Lumexa Imaging (NASDAQ:LMRI) is trading down 3.63% at $15.37, giving back part of Wednesday's 14.58% jump to $15.95. Third quarter adjusted Earnings of $0.26 per share beat the roughly $0.18 analysts expected, and the outpatient imaging provider raised its full-year earnings outlook.
Quarter Results
Revenue rose 5% to $272 million, with system-wide outpatient Revenue up 7.7% and Volume up 4.9%, the strongest of 2026. Advanced modality mix reached a record. Adjusted EBITDA was $62.6 million, a 23.0% margin. GAAP earnings were $0.07 per share, and Net Income was $7.2 million versus a $3.5 million loss a year ago.
Balance Sheet Progress
Free Cash Flow was $20.6 million, and cash stood at $90 million. Net leverage fell to 3.5 times from 5.6 times a year earlier, a major step for a company that recently went public.
Guidance Details
Adjusted EBITDA guidance was narrowed to $236 million to $240 million, with the $238 million midpoint unchanged. Revenue guidance of $1.045 billion to $1.097 billion was reiterated. Adjusted EPS guidance rose to $0.86 to $0.90 from $0.71 to $0.77, mainly because of a lower tax rate rather than stronger operations. Free cash flow conversion is expected at 30% or more of adjusted EBITDA.
Policy and Expansion
A final site-neutral payment rule expands the addressable market to about $77 billion by moving more imaging into lower-cost outpatient settings. Lumexa also added a joint venture with Advocate Health in Illinois, bringing its total to 10. Raymond James holds a $19 target with a Strong Buy rating.
Operations, Not Tax, Decide the Next Move
After a 14.58% jump, today's pullback reflects questions over how much of the raise is tax-driven. With the EBITDA midpoint unchanged, investors will watch whether volume growth near 5% holds, whether advanced modality mix keeps rising and whether new joint ventures add to revenue.
Fourth quarter volume and leverage below 3.5 times are the next markers.






Please wait processing your request...